Gujarat Kidney and Super Speciality Share News - Latest Updates, Live News & More

Latest news about Gujarat Kidney and Super Speciality

Gujarat Kidney Q1 Results: Net profit rises to 52M rupees, revenue more than doubles YoY 3 hrs ago Today

Gujarat Kidney and Super Speciality posted a consolidated net profit of 52M rupees in Q1, compared to 48M rupees in the year-ago period. Revenue surged to 343M rupees from 153M rupees on a year-on-year basis, reflecting significant topline expansion. Both metrics improved year-on-year, with revenue more than doubling while net profit recorded modest growth.

Gujarat Kidney seeks vote to reallocate IPO proceeds Jul 23, 2026

Gujarat Kidney appoints Paresh Dhoti as Non-Executive Non-Independent Director Jul 21, 2026

Gujarat Kidney acquires 51% stake in Blue Tree Clinics LLC, UAE Jul 13, 2026

Gujarat Kidney corrects signing date error in Q1FY26 results Jul 11, 2026

More news about Gujarat Kidney and Super Speciality

07Jul 26

Gujarat Kidney approves variation in IPO proceeds utilisation

Gujarat Kidney and Super Speciality Limited received shareholder approval to vary the objects and terms of utilisation of its IPO proceeds via a postal ballot. The special resolution passed with 99.9995% of votes in favour, with 56,894,699 votes supporting the proposal and 286 against.

05Jun 26

Gujarat Kidney seeks nod to vary IPO proceeds utilization

Gujarat Kidney And Superspeciality Limited has initiated a remote e-voting process from June 05 to July 04, 2026, to seek shareholder approval for varying the utilization of its IPO proceeds. The company proposes to reallocate Rs 37.76 crore, utilizing Rs 6.12 crore for healthcare expansion in its subsidiary and parent company, and transferring Rs 19.02 crore to fund inorganic growth and general corporate purposes. The decision follows a review of a previous proposal to incorporate a new subsidiary, aiming to avoid duplication of resources. The results of the postal ballot will be announced on or before July 07, 2026.

29May 26

Gujarat Kidney FY26 profit rises, appoints auditors

Gujarat Kidney And Superspeciality Limited reported its audited standalone and consolidated financial results for the year ended March 31, 2026, showing a rise in standalone profit after tax to ₹990.14 lacs and consolidated profit after tax to ₹1,681.18 lacs. The board appointed internal and secretarial auditors and deferred the CEO appointment while seeking shareholder approval for a variation in its IPO objects via postal ballot.

28May 26

Gujarat Kidney promoters declare no encumbrance in FY26

Gujarat Kidney and Super Speciality Limited confirmed via a regulatory filing that its promoters did not encumber any shares during FY26. The disclosure, signed by promoter Pragnesh Bharpoda, was submitted to BSE and NSE on April 7, 2026, under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

15May 26

Gujarat Kidney and Super Speciality to Deploy 100 AI-Powered Haemodialysis Machines Across Gujarat Network

Gujarat Kidney and Super Speciality Limited has announced the procurement of 100 AI-enabled haemodialysis machines, with Phase-1 deployment of 8 units at its Gujarat Multi Speciality Hospital, Godhra facility within 10 days of the announcement dated 14 May 2026. The AI-powered machines offer real-time decision support, early complication detection, and personalised treatment parameters, with the remaining units to be progressively deployed across GKSL's dialysis centre network across Gujarat.

25Apr 26

Gujarat Kidney and Super Speciality Limited Postal Ballot Results: All Resolutions Approved

Gujarat Kidney and Super Speciality Limited shareholders approved all three resolutions through postal ballot on 25-04-2026, including healthcare expansion funding (100% approval), voluntary revision of financial statements under Section 131 (99.9998% approval), and appointment of Mr. Dharmendra Bhaliya as Secretarial Auditor for FY 2025-26 (99.9994% approval). The e-voting process conducted from 27th March to 25th April 2026 achieved 72.1003% participation with 56,846,254 votes cast out of 78,843,250 total shares.

22Apr 26

Gujarat Kidney Pays Rs 20,000 Fines to BSE and NSE for Board Meeting Delay

Gujarat Kidney and Super Speciality Limited has paid Rs 20,000 in total fines to BSE and NSE for failing to provide prior intimation about board meetings under SEBI Regulation 29(2)/29(3). The penalties of Rs 10,000 each were imposed on April 15, 2026, and paid via NEFT on April 16, 2026. The company confirmed no impact on financial, operational, or other activities.

07Apr 26

Gujarat Kidney and Super Speciality Limited Submits SEBI Compliance Certificate for Q4FY26

Gujarat Kidney and Super Speciality Limited has submitted its mandatory SEBI compliance certificate for Q4FY26, confirming all shares are in electronic form. The certificate, issued by registrar MUFG Intime India Private Limited on April 6, 2026, was submitted to BSE and NSE on April 7, 2026, fulfilling Regulation 74(5) requirements for the quarter ended March 31, 2026.

26Mar 26

Gujarat Kidney Completes Postal Ballot Notice Dispatch for IPO Fund Reallocation

Gujarat Kidney and Super Speciality Limited has completed the dispatch of its postal ballot notice to shareholders, announcing through newspaper publications on March 26, 2026. The company seeks approval for reallocating ₹3,692.50 lakhs of unutilized IPO funds from women's hospital and robotics equipment to developing a multi-specialty hospital in Bharuch and dialysis services collaboration. The e-voting process runs from March 27 to April 25, 2026, with results expected within two working days.

23Mar 26

Gujarat Kidney and Super Speciality Limited Acquires Parekhs Hospital for ₹77 Crore

Gujarat Kidney and Super Speciality Limited completed acquisition of Parekhs Hospital Private Limited as wholly owned subsidiary on March 22, 2026, for ₹77 crore cash consideration. The target company, incorporated in 2006, operates in medical and healthcare services with revenues of ₹25.67 crore in FY25. The strategic acquisition aims to strengthen presence in healthcare sector and diversify business portfolio.

21Mar 26

Gujarat Kidney Pays ₹6.61 Lakh Penalty to NSE and BSE for Regulatory Non-Compliance

Gujarat Kidney and Super Speciality Limited has completed payment of regulatory penalties totaling ₹6,60,800 to NSE and BSE for failing to submit quarterly financial results within prescribed timelines. The company paid ₹3,30,400 to each exchange via RTGS on March 20, 2026, following penalty notices received on March 17, 2026, and has formally communicated the settlement to both exchanges.

19Mar 26

Gujarat Kidney Appoints Auditors and Approves Postal Ballot with Q2 FY25 Results

Gujarat Kidney And Superspeciality Limited conducted a board meeting on March 19, 2026, appointing Mr. Dharmendra Bhaliya as Secretarial Auditor and Mr. Siddharth Atulbhai Shah as Internal Auditor for FY 2025-26. The board also approved postal ballot notice and ratified Q2 FY25 financial results, which showed consolidated revenue growth of 37.40% to ₹1,292.88 lacs despite a decline in net profit.

13Mar 26

Gujarat Kidney And Super Speciality Limited Reports Mixed Q2FY26 Results with Revenue Decline

Gujarat Kidney And Super Speciality Limited reported Q2FY26 standalone revenue of ₹964.26 lacs, up 2.47% YoY, but net profit declined 22.17% to ₹230.12 lacs due to rising expenses. Half-year performance showed stronger growth with revenue increasing 12.97% to ₹2,109.25 lacs and net profit rising 10.12% to ₹620.10 lacs. Consolidated results demonstrated significant revenue growth of 37.40% to ₹1,292.88 lacs, reflecting successful expansion through subsidiaries, though profitability remained under pressure with EPS declining across both standalone and consolidated operations.

Gujarat Kidney and Super Speciality

136.43

+0.25

(+0.18%)

1 Year Returns:+30.51%

Industry Peers

Apollo Hospitals

8,920.50

(+3.85%)

Max Healthcare Institute

1,008.60

(-0.46%)

Fortis Healthcare

929.00

(+2.52%)

Aster DM Quality Care

822.35

(-0.24%)

Global Health

1,422.60

(+0.90%)

Narayana Hrudayalaya

1,832.60

(+0.09%)

Krishna Institute of Medical Sciences

809.10

(+0.19%)

Dr. Agarwal's Health Care

506.50

(-0.39%)

Rainbow Childrens Medicare

1,461.80

(+0.61%)

Park Medi World

281.35

(+0.09%)

Get More Market Insights with

Stock Rental via SLBM

About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

Part of Raise Financial Services

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357 Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104